Chemokines in Cancer

Griffith, 2014, Chemokines and chemokine receptors: positioning cells for host defense and immunity, Annu Rev Immunol, 32, 659, 10.1146/annurev-immunol-032713-120145

Charo, 2006, The many roles of chemokines and chemokine receptors in inflammation, N Engl J Med, 354, 610, 10.1056/NEJMra052723

Balkwill, 2004, Cancer and the chemokine network, Nat Rev Cancer, 4, 540, 10.1038/nrc1388

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Wani, 2014, CXC motif chemokine 12/CXC chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment, Breast Cancer Res, 16, R54, 10.1186/bcr3665

Chen, 2012, Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis, J Clin Invest, 122, 3184, 10.1172/JCI62110

Bolitho, 2010, The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor, Endocr Relat Cancer, 17, 929, 10.1677/ERC-10-0107

Su, 2011, Chemokine receptor CXCR4-mediated transformation of mammary epithelial cells by enhancing multiple RTKs expression and deregulation of the p53/MDM2 axis, Cancer Lett, 307, 132, 10.1016/j.canlet.2011.03.025

Song, 2012, Deficiency of CC chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model, PLoS ONE, 7, e33747, 10.1371/journal.pone.0033747

Payne, 2002, The role of chemokines in melanoma tumor growth and metastasis, J Invest Dermatol, 118, 915, 10.1046/j.1523-1747.2002.01725.x

Smith, 2004, CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res, 64, 8604, 10.1158/0008-5472.CAN-04-1844

Luker, 2006, Functions of CXCL12 and CXCR4 in breast cancer, Cancer Lett, 238, 30, 10.1016/j.canlet.2005.06.021

Lau, 2014, Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts, J Pathol, 232, 43, 10.1002/path.4258

Mishra, 2011, Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy, J Leukoc Biol, 89, 31, 10.1189/jlb.0310182

Rigo, 2010, Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12, Mol Cancer, 9, 273, 10.1186/1476-4598-9-273

Bergers, 2003, Tumorigenesis and the angiogenic switch, Nat Rev Cancer, 3, 401, 10.1038/nrc1093

Strieter, 2005, CXC chemokines in angiogenesis, Cytokine Growth Factor Rev, 16, 593, 10.1016/j.cytogfr.2005.04.007

Tachibana, 1998, The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract, Nature, 393, 591, 10.1038/31261

Nagasawa, 1996, Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1, Nature, 382, 635, 10.1038/382635a0

Salcedo, 2003, Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses, Microcirculation, 10, 359, 10.1080/mic.10.3-4.359.370

Martin, 2009, CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1) complex, J Biol Chem, 284, 6038, 10.1074/jbc.C800207200

Ueno, 2000, Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer, Clin Cancer Res, 6, 3282

Perollet, 1998, Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization, Blood, 91, 3289, 10.1182/blood.V91.9.3289

Luster, 1995, The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation, J Exp Med, 182, 219, 10.1084/jem.182.1.219

Campanella, 2010, CXCL10 can inhibit endothelial cell proliferation independently of CXCR3, PLoS ONE, 5, e12700, 10.1371/journal.pone.0012700

Dimberg, 2010, Chemokines in angiogenesis, Curr Top Microbiol Immunol, 59

Nguyen, 2009, Metastasis: from dissemination to organ-specific colonization, Nat Rev Cancer, 9, 274, 10.1038/nrc2622

Zlotnik, 2011, Homeostatic chemokine receptors and organ-specific metastasis, Nat Rev Immunol, 11, 597, 10.1038/nri3049

Müller, 2001, Involvement of chemokine receptors in breast cancer metastasis, Nature, 410, 50, 10.1038/35065016

Darash-Yahana, 2004, Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis, FASEB J, 18, 1240, 10.1096/fj.03-0935fje

Marchesi, 2004, Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4, Cancer Res, 64, 8420, 10.1158/0008-5472.CAN-04-1343

Schimanski, 2005, Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer, Clin Cancer Res, 11, 1743, 10.1158/1078-0432.CCR-04-1195

Kang, 2005, The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer, Breast, 14, 360, 10.1016/j.breast.2004.12.007

Das, 2013, Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses, J Exp Med, 210, 1509, 10.1084/jem.20111627

Dighe, 1994, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors, Immunity, 1, 447, 10.1016/1074-7613(94)90087-6

Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, 29, 235, 10.1146/annurev-immunol-031210-101324

Groom, 2011, CXCR3 in T cell function, Exp Cell Res, 317, 620, 10.1016/j.yexcr.2010.12.017

Groom, 2012, CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation, Immunity, 37, 1091, 10.1016/j.immuni.2012.08.016

Wendel, 2008, Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands, Cancer Res, 68, 8437, 10.1158/0008-5472.CAN-08-1440

Hensbergen, 2005, The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis, J Immunother, 28, 343, 10.1097/01.cji.0000165355.26795.27

Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines, Cancer Res, 72, 5209, 10.1158/0008-5472.CAN-12-1187

Andersson, 2009, IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer, J Immunol, 182, 6951, 10.4049/jimmunol.0803340

Oghumu, 2014, CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model, Immunology, 143, 109, 10.1111/imm.12293

Biswas, 2010, Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, Nat Immunol, 11, 889, 10.1038/ni.1937

González-Martín, 2011, Maximal T cell–mediated antitumor responses rely upon CCR5 expression in both CD4+ and CD8+ T cells, Cancer Res, 71, 5455, 10.1158/0008-5472.CAN-11-1687

Josefowicz, 2012, Regulatory T cells: mechanisms of differentiation and function, Annu Rev Immunol, 30, 531, 10.1146/annurev.immunol.25.022106.141623

Teng, 2010, Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth, Cancer Res, 70, 7800, 10.1158/0008-5472.CAN-10-1681

Klages, 2010, Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma, Cancer Res, 70, 7788, 10.1158/0008-5472.CAN-10-1736

Li, 2010, Efficient Treg depletion induces T-cell infiltration and rejection of large tumors, Eur J Immunol, 40, 3325, 10.1002/eji.201041093

Bos, 2013, Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy, J Exp Med, 210, 2435, 10.1084/jem.20130762

Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, 10, 942, 10.1038/nm1093

Facciabene, 2011, Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells, Nature, 475, 226, 10.1038/nature10169

Olkhanud, 2009, Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells, Cancer Res, 69, 5996, 10.1158/0008-5472.CAN-08-4619

Koch, 2009, The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation, Nat Immunol, 10, 595, 10.1038/ni.1731

Hoerning, 2011, Subsets of human CD4+ regulatory T cells express the peripheral homing receptor CXCR3, Eur J Immunol, 41, 2291, 10.1002/eji.201041095

Suga, 2013, CXCR3 deficiency prolongs Th1-type contact hypersensitivity, J Immunol, 190, 6059, 10.4049/jimmunol.1201606

Redjimi, 2012, CXCR3 +T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity, Cancer Res, 72, 4351, 10.1158/0008-5472.CAN-12-0579

Gabrilovich, 2012, Coordinated regulation of myeloid cells by tumours, Nat Rev Immunol, 12, 253, 10.1038/nri3175

Schlecker, 2012, Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth, J Immunol, 189, 5602, 10.4049/jimmunol.1201018

Liu, 2011, Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice, PLoS ONE, 6, e19495, 10.1371/journal.pone.0019495

Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014

Mantovani, 2004, The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol, 25, 677, 10.1016/j.it.2004.09.015

Aldinucci, 2014, The inflammatory chemokine CCL5 and cancer progression, Mediators Inflamm, 2014, 292376, 10.1155/2014/292376

Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu Rev Immunol, 31, 51, 10.1146/annurev-immunol-032712-100008

Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, 12, 298, 10.1038/nrc3245

Ma, 2014, CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy, Cancer Res, 74, 436, 10.1158/0008-5472.CAN-13-1265

Hong, 2011, Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control, Cancer Res, 71, 6997, 10.1158/0008-5472.CAN-11-1466

Lim, 2014, Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells, Cancer Immunol Immunother, 63, 259, 10.1007/s00262-013-1506-7

Acharyya, 2012, A CXCL1 paracrine network links cancer chemoresistance and metastasis, Cell, 150, 165, 10.1016/j.cell.2012.04.042

Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies, J Exp Med, 206, 1717, 10.1084/jem.20082492

Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073/pnas.0915174107

Rosenberg, 2008, Adoptive cell transfer: a clinical path to effective cancer immunotherapy, Nat Rev Cancer, 8, 299, 10.1038/nrc2355

Bellone, 2013, Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes, Front Oncol, 3, 231, 10.3389/fonc.2013.00231

Scott, 2012, Antibody therapy of cancer, Nat Rev Cancer, 12, 278, 10.1038/nrc3236

El Annan, 2010, Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye–associated corneal inflammation, Invest Ophthalmol Vis Sci, 51, 3418, 10.1167/iovs.09-3684

Pauken, 2013, PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes, Diabetes, 62, 2859, 10.2337/db12-1475

Schall, 2011, Overcoming hurdles in developing successful drugs targeting chemokine receptors, Nat Rev Immunol, 11, 355, 10.1038/nri2972